Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Cancers|April 26, 2025
Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1qMagdalena Benda, Patrick Reimann, Elena Bletzacher, et al.
Annals of Hematology|February 26, 2011
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patientsMichael Fiegl, Florian Falkner, Michael Steurer, et al.
British Journal of Haematology|January 30, 2020
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short reportUdvardy Miklos, Vladimir Strugov, Catharina Lewerin, et al.
Acta Haematologica|June 13, 2015
Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and SeverityAnn Janssens, Michael Tarantino, Robert J Bird, et al.
American Journal of Hematology|September 16, 2020
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic eventMaurus Locher, Michael Steurer, Emina Jukic, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Wiener Klinische Wochenschrift|September 17, 2015
Iron metabolism and iron supplementation in cancer patientsHeinz Ludwig, Rayko Evstatiev, Gabriela Kornek, et al.
Haematologica|May 18, 2019
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemiaMichael Steurer, Marco Montillo, Lydia Scarfò, et al.
Leukemia & Lymphoma|January 20, 2016
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemiaAnders Österborg, Miklós Udvardy, Andrey Zaritskey, et al.
Pageof 10